跳至主要内容
临床试验/JPRN-jRCTs061220050
JPRN-jRCTs061220050招募中2 期

Improvement effect and safety of overactive bladder symptoms by 5-aminolevulinic acid (5-ALA) intake;Double-blind randomized placebo-controlled trial

Fukata Satoshi0 个研究点目标入组 100 人开始时间: 2022年8月29日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 30age old 至 ot applicable(—)
性别
All

入选标准

  • All of the following criteria must be met in order to
  • participate in this trial.
  • 1.Patients with overactive bladder over 30 years
  • 2.Patients with overactive bladder who consented
  • to participate in the study in writing

排除标准

  • If any of the following criteria are met, the patient
  • will not be allowed to participate in this trial.
  • 1.Patients with organic disease of the urinary tract
  • 2.Patients with neurogenic overactive bladder
  • 3.Patients with malignant tumors of the urinary sys
  • 4.Patients with cognitive dysfunction or psychiatri
  • c disorders that are difficult to conduct research
  • 5.Patients who are allergic to 5-ALA
  • 6.Patients with porphyria
  • 7.Patients with drug hypersensitivity such as iron a
  • 8.Pregnant women or patients who may become p
  • 9.Patients who did not consent to participate in th
  • e study in writing
  • 10.Patients disqualified by a doctor

研究者

发起方
Fukata Satoshi

相似试验